A somatostatin receptor scintigraphy (SRS) was performed in 13 patients with hodgkin (n = 1) or non-hodgkin (n = 12) lymphomas before any treatment, and then during treatment for four of them. SRS datas were compared to those of conventional methods (clinical data, thoraco-abdominal CT, osteomedullar biopsy). Before treatment, only 25 out of 38 (66%) known extra-medullar tumoral localizations were visualized with SRS, among which 81% of the extra-abdominal lesions, and 44% of the abdominal ones. Five hot spots (five patients) did not correspond to any known localization. For one of them, the histological confirmation was obtained, changing both the stage and the treatment of the disease. Tumoral uptake was highly variable from one patient to another (a tumor / background ratio was calculated for each localization), similar from one site to another in the same patient, and most often low (2 of the patients had a ratio < 2.5). In one patient, none of the tumoral sites were detected by SRS. During treatment, conventional methods and SRS were concordant in three cases (complete remission / SRS normalized), and discordant in one case (complete remission / residual uptake in the initial tumoral site). So SRS diagnostic accuracy compared to conventional methods depends on tumoral uptake and localization. It could be useful in the patients follow-up, but other studies are needed to assess its specificity, and to confirm the correlation between residual tracer uptake and remnant active tumoral tissue.